Suchergebnisse - "De Giorgi, Ugo"

PubPharm (40)

1

Enzalutamide and leuprolide acetate in non-metastatic hormone-sensitive prostate cancer : the sooner the better?

enthalten in: Future oncology (London, England) | 2024

von Giunta, E. | Gasperoni, L. | De Giorgi, U.

2

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)

enthalten in: Therapeutic advances in medical oncology | 2024

von Sepe, P. | Procopio, G. | Pircher, C. | +16

3

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer : the phase 3 TALAPRO-2 trial

enthalten in: Nature medicine | 2024

von Fizazi, K. | Azad, A. | Matsubara, N. | +18

ErratumIn: Nat Med. 2024 Jan 31;:. - PMID 38297094

4

Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer

enthalten in: NEJM evidence | 2023

von Freedland, S. | Gleave, M. | De Giorgi, U. | +14

5

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

enthalten in: The New England journal of medicine | 2023

von Freedland, S. | de Almeida Luz, M. | De Giorgi, U. | +17

CommentIn: N Engl J Med. 2024 Jan 4;390(1):90. - PMID 38169497

6

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2) : a randomised, placebo-controlled, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Agarwal, N. | Azad, A. | Carles, J. | +18

CommentIn: Lancet. 2023 Jul 22;402(10398):266-267. - PMID 37285866

7

A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

enthalten in: The Prostate | 2023

von Fernandez-Perez, M. | Perez-Navarro, E. | Alonso-Gordoa, T. | +28

8

Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes : A Post Hoc Analysis of the PROSPER Randomized Clinical Trial

enthalten in: The Journal of urology | 2023

von Hussain, M. | Sternberg, C. | Efstathiou, E. | +9

9

Rucaparib or Physician's Choice in Metastatic Prostate Cancer

enthalten in: The New England journal of medicine | 2023

von Fizazi, K. | Piulats, J. | Reaume, M. | +126

CommentIn: Nat Rev Urol. 2023 Apr;20(4):199. - PMID 36928618

10

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

enthalten in: Journal of translational medicine | 2023

von Nuzzo, P. | Pederzoli, F. | Saieva, C. | +16